Episode Details
Back to Episodes
Pharmaceutical Executive Daily: Ultragenyx Sells Rare Pediatric Disease Priority Review Voucher
Published 1 month, 1 week ago
Description
Ultragenyx sells a rare pediatric disease priority review voucher for $210 million, Viatris acquires Pacira BioSciences for $1.65 billion, and Peter Young surveys a steadying biopharma outlook.